1-Piperidinecarboxylic acid, 4-(phenylmethyl)-, 4-nitrophenyl ester | 628717-19-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Piperidinecarboxylic acid, 4-(phenylmethyl)-, 4-nitrophenyl ester
• 英文别名: (4-nitrophenyl) 4-benzylpiperidine-1-carboxylate
• CAS: 628717-19-1
• 化学式: C₁₉H₂₀N₂O₄
• 分子量: 340.379
• InChiKey: IMDYVHIBOROIMV-UHFFFAOYSA-N

物化性质

• 熔点：
  92-94 °C
• 沸点：
  497.8±37.0 °C(Predicted)
• 密度：
  1.256±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  75.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  对硝基苯酚 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 13.0h， 生成 1-Piperidinecarboxylic acid, 4-(phenylmethyl)-, 4-nitrophenyl ester
  参考文献：
  名称：

  Synthesis and evaluation of esters and carbamates to identify critical functional groups for esterase-specific metabolism

  摘要：

  In an effort to develop novel prodrugs for viral directed enzyme prodrug therapy (VDEPT) approaches to chemotherapy, eleven esters and carbamates of o-nitrophenol, p-nitrophenol, and beta-naphthol were synthesized and characterized as substrates for rabbit (rCE) and human liver (hCE1) carboxylesterases. All of the esters of o-, p-nitrophenols, and beta-naphthols showed moderate hydrolysis by both rCE and hCE1. Esters of beta-naphthols exhibited higher hydrolysis rates compared to esters of p-nitrophenols by rCE. Of the carbamates, 4-benzyl-piperazine-1-carboxylic acid 2-nitrophenol showed preferential hydrolysis by rCE compared to hCE1 with a V-max of 54.4 mumoles/min/mg, and a K-m value of 1071 muM. Substrate metabolism by a specific CE or inhibition of CEs by each compound depended on several factors, including the types of functional groups and linking moieties. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00302-x

文献信息

• COMBINED DRUG ADMINISTRATION
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2373344A1

  公开（公告）日：2011-10-12
• NOVEL COMBINED ADMINISTRATION
  申请人：Gross Guenter

  公开号：US20100144853A1

  公开（公告）日：2010-06-10

  The present invention is directed to the combined administration of a thioester therapeutic agent (preferably of formula I) and at least one esterase inhibitor. Also provided are a pharmaceutical composition, package, and a kit comprising the aforementioned active ingredients, as well as a method for increasing the bioavailability of said thioester for the treatment and prophylaxis of a cardiovascular disorder.
• COMBINED DRUG ADMINISTRATION OF DALCETRAPIB AND ORLISTAT
  申请人：Hoffmann-La Roche Inc.

  公开号：US20160074360A1

  公开（公告）日：2016-03-17

  The present invention is directed to the combined administration of a thioester therapeutic agent (preferably of formula I) and at least one esterase inhibitor. Also provided are a pharmaceutical composition, package, and a kit comprising the aforementioned active ingredients, as well as a method for increasing the bioavailability of said thioester for the treatment and prophylaxis of a cardiovascular disorder.
• [EN] COMBINED DRUG ADMINISTRATION<br/>[FR] ADMINISTRATION COMBINÉE DE MÉDICAMENTS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010066593A1

  公开（公告）日：2010-06-17

  The present invention is directed to the combined administration of and. The invention provides a combination comprising (a) a thioester or prodrug of the active form thereof, and (b) at least one an esterase inhibitor. Also provided are a pharmaceutical composition, package, and a kit comprising the aforementioned active ingredients, as well as a method for treatment and prophylaxis of a cardiovascular disorder involving the use of the aforementioned active ingredients.